| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE48960 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 9 months from now) | |
| US9447415 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(1 year, 9 months from now) | |
| US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
| US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
| US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(7 years from now) | |
Amondys 45 is owned by Sarepta Theraps Inc.
Amondys 45 contains Casimersen.
Amondys 45 has a total of 6 drug patents out of which 0 drug patents have expired.
Amondys 45 was authorised for market use on 25 February, 2021.
Amondys 45 is available in solution;intravenous dosage forms.
Amondys 45 can be used as treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by inducing exon-skipping of exon 45; treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping, treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production, treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production.
Drug patent challenges can be filed against Amondys 45 from 2025-02-25.
The generics of Amondys 45 are possible to be released after 12 November, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 25, 2028 |
| New Chemical Entity Exclusivity (NCE) | Feb 25, 2026 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 2025-02-25
Market Authorisation Date: 25 February, 2021
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; Treatment of duchenne muscular dystrophy (dmd) in patients who have...
Dosage: SOLUTION;INTRAVENOUS
AMONDYS 45 family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic